| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | 1 | — | — | 4 | — | — | 1 | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2023 | ‡‡‡ |
|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2020 | ‡‡‡ |
|
| 2019 | ‡‡‡ |
|
| 2017 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 76.33 | 52.89 | 40.27 | 50.77 |
| Receivables | 50.70 | 52.48 | 25.39 | 0.03 |
| Inventory | — | — | — | — |
| Other | — | — | — | — |
| 131.21 | 107.28 | 67.29 | 51.58 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 1.38 | 7.31 | 0.69 | 0.16 |
| ST’ Debt | — | — | — | — |
| Other | — | — | — | — |
| 37.15 | 49.07 | 8.87 | 8.43 |
| 10y | 5y | 3y | |
| Sales | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Earnings | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Book Value | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 0.26 | — | — | — |
—
|
| ’25 | 5.87 | 14.19 | 5.44 | 41.30 |
66.80
|
| ’24 | 9.27 | 10.20 | 13.47 | 15.04 |
47.98
|
| ’23 | 2.07 | 2.72 | 25.47 | 73.52 |
103.78
|
| ’22 | 2.07 | 1.99 | 2.01 | 47.44 |
53.51
|
| ’21 | 7.30 | 5.15 | 3.06 | 2.74 |
18.26
|
| ’20 | 1.70 | 1.73 | 4.00 | 1.91 |
9.33
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 15.86 | (5.35) | — | — |
—
|
| ’25 | (4.00) | (17.69) | 17.42 | (8.35) |
(12.62)
|
| ’24 | 5.94 | (18.74) | 12.76 | (23.40) |
(23.44)
|
| ’23 | (12.85) | (18.56) | 15.92 | (17.49) |
(32.99)
|
| ’22 | (28.22) | (23.03) | (0.96) | 44.48 |
(7.73)
|
| ’21 | (15.48) | (16.57) | (4.95) | (27.35) |
(64.35)
|
| ’20 | (23.33) | (24.90) | (21.26) | (16.38) |
(85.87)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 15.86 | (5.35) | — | — |
—
|
| ’25 | (4.00) | (17.69) | 17.42 | (8.35) |
(12.62)
|
| ’24 | 5.94 | (18.74) | 12.76 | (23.40) |
(23.44)
|
| ’23 | (12.85) | (18.56) | 15.92 | (17.49) |
(32.99)
|
| ’22 | (28.22) | (23.03) | (0.96) | 44.48 |
(7.73)
|
| ’21 | (15.48) | (16.57) | (4.95) | (27.31) |
(64.31)
|
| ’20 | (23.41) | (24.91) | (21.31) | (16.39) |
(86.03)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.13) | (0.16) | — | — |
—
|
| ’25 | (0.25) | (0.03) | (0.13) | 0.53 |
0.15
|
| ’24 | (0.24) | (0.33) | (0.32) | (0.38) |
(1.27)
|
| ’23 | (0.25) | (0.23) | (0.06) | 0.96 |
0.43
|
| ’22 | (1.01) | (0.87) | (0.33) | 0.55 |
(1.23)
|
| ’21 | (0.66) | (0.63) | (0.70) | (0.90) |
(2.91)
|
| ’20 | (1.22) | (0.85) | (0.86) | (0.68) |
(3.52)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | 0.68 | 0.99 | 0.92 | 0.51 | — | — | — |
Low Price
|
| — | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 16.30 | 2.04 | 1.89 | 3.22 | — | — | — |
High Price
|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | 35 | 46 | 32 | 25 | — | — | — |
Employees
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.53 | 2.26 | 1.50 | 2.67 | — | — | — |
Revenue/Emp
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 53.51 | 103.78 | 47.98 | 66.80 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Revenue
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 100.00% | 100.00% | 100.00% | 100.00% | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (46.41) | 25.40 | (68.57) | 8.83 | — | — | — |
EBT
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (86.74%) | 24.48% | (142.91%) | 13.22% | ‡‡‡ | ‡‡‡ | — |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (46.41) | 22.81 | (68.57) | 8.57 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.87 | 0.37 | 0.00 | — | — | — | — |
Depreciation
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.42 | 1.97 | 0.89 | 1.19 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Revenue/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.23) | 0.43 | (1.27) | 0.15 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.21) | (0.63) | (0.43) | (0.23) | — | — | — |
Cash Flow/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡ | ‡‡‡ | — |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.21) | (0.63) | (0.43) | (0.23) | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.02 | 2.03 | 0.85 | 1.05 | — | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 37.59 | 52.70 | 54.04 | 56.02 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Shares
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 3.53 | 0.00 | 15.53 | ‡‡‡‡ | ‡‡‡‡ | — |
PE Ratio
|
| ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.22 | 0.77 | 1.16 | 1.95 | ‡‡‡ | ‡‡‡ | — |
PS Ratio
|
| ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.86 | 0.75 | 1.21 | 2.21 | ‡‡‡ | ‡‡‡ | — |
PB Ratio
|
| ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.69) | 0.09 | 0.18 | 1.44 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
EV/Sales
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 4.77 | (0.29) | (0.37) | (7.59) | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (7.73) | (32.99) | (23.44) | (12.62) | ‡‡‡ | ‡‡‡ | — |
Op' Cash Flow
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | — | — | ‡‡‡‡‡ | — | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (7.73) | (32.99) | (23.44) | (12.62) | — | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 91.92 | 94.06 | 58.20 | 58.42 | — | — | — |
Working Cap'
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 6.65 | — | — | — | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (102.46) | (76.33) | (52.89) | (40.26) | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 75.93 | 106.89 | 46.12 | 59.02 | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (31.37%) | 14.85% | (46.81%) | 9.55% | — | — | — |
ROA
|
| ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | 0.00% | 43.93% | 0.00% | 21.04% | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (56.53%) | 24.95% | (89.62%) | 16.31% | — | — | — |
ROE
|
Spero Therapeutics (SPRO), a clinical-stage biotech targeting multi-drug resistant infections, exemplifies the sector’s extreme volatility: after years of R&D-driven losses, 2023 delivered a rare profit spike from FDA-approved XACDURO, fueling revenue growth to $104 million and positive EPS. Yet 2024 reversed fortunes with a 54% revenue plunge to $48 million, renewed deep losses (EPS -$1.27), and eroding shareholder equity down 57% to $46 million amid persistent negative free cash flow. Trading 67% below consensus targets, the stock reflects commercialization hurdles, pipeline dependence, and biotech’s binary risks.
While gross margins remain at 100% and working capital provides a buffer, aggressive headcount cuts (78% since 2021) signal execution strains, with forecasts predicting further revenue cliffs to $0.8 million in 2026 before a tentative rebound. Insider selling without buys adds caution, as balance sheet resilience frays under cash burn exceeding $400 million historically. Valuation multiples like EV/Sales at 0.18x appear depressed, but forward projections hinge on unproven catalysts like tebipenem Phase 3.
For risk-averse investors, Spero warrants only a tiny 1-2% speculative allocation, dwarfed by steadier pharma giants—history of 80%+ drawdowns and late-stage approval odds below 50% demand vigilance. Full analysis unpacks these swings, insider signals, and Q1 2026 catalysts that could validate upside or expose deeper downside.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.